Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).


ABULKHAIR O., USLU R., SEZGIN C., BUEYUEKBERBER S., DARWISH T., ISIKDOGAN A., ...More

CANCER RESEARCH, vol.72, 2012 (Journal Indexed in SCI) identifier